SCHEMBL26093496

SCHEMBL26093496

CSC1=N/C(=C\c2ccc3cnccc3c2)C(=O)N1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.58
▸ HPGD P15428 2/20 0.58
▸ GAA P10253 1/20 0.58
▸ DYRK3 O43781 4/20 0.56
▸ DYRK1A Q13627 4/20 0.56
▸ DYRK2 Q92630 4/20 0.56
▸ DYRK1B Q9Y463 4/20 0.56
▸ PIM1 P11309 3/20 0.56
▸ CSNK2A2 P19784 3/20 0.56
▸ CSNK2B P67870 3/20 0.56
▸ CSNK2A1 P68400 3/20 0.56
▸ CSNK2A3 Q8NEV1 3/20 0.56
▸ KDM4E B2RXH2 2/20 0.51
▸ CNR1 P21554 1/20 0.47
▸ CNR2 P34972 1/20 0.47
▸ GPR18 Q14330 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.44
▸ CYP3A4 P08684 8/20 0.38
▸ CA2 P00918 2/20 0.37
▸ CLK1 P49759 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30363333 1.00 MAPT (0.58) MAPTHPGDGAADYRK3DYRK1A
SCHEMBL30363327 0.87 MAPT (0.63) MAPTHPGDGAADYRK3DYRK1A
SCHEMBL26096057 0.87 MAPT (0.63) MAPTHPGDGAADYRK3DYRK1A
SCHEMBL26096202 0.81 MAPT (0.58) MAPTHPGDGAADYRK3DYRK1A
SCHEMBL30363342 0.77 MAPT (0.57) MAPTHPGDGAADYRK3DYRK1A
SCHEMBL26095459 0.77 MAPT (0.57) MAPTHPGDGAADYRK3DYRK1A
SCHEMBL26095879 0.76 MAPT (0.56) MAPTHPGDGAADYRK3DYRK1A
SCHEMBL26092928 0.76 MAPT (0.62) MAPTHPGDGAADYRK3DYRK1A
SCHEMBL30363453 0.76 MAPT (0.62) MAPTHPGDGAADYRK3DYRK1A
SCHEMBL26104192 0.75 MAPT (0.59) MAPTGAADYRK3DYRK1ADYRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340538-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2025-11-06 — — US disclosed
WO-2023072969-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-05-04 — — WO disclosed
EP-4173674-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 Perha Pharmaceuticals (FR) 2023-05-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340538-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 CLK1, CLK2, CLK3 MAPT 330/4885HPGD 3481/4885GAA 4344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback